This case-based session will address the most common cause of liver disease namely metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. The audience will become familiar with the new nomenclature, epidemiology, clinical diagnosis, and risk-stratification using non-invasive tests. In addition, practical approaches to MASLD treatment including newly approved medications will be discussed. Join this session to: (1) gain insights into the spectrum of steatotic liver disease and (2) enhance knowledge of MASLD diagnostic and new therapeutic strategies in clinical practice.
CROI Conference
